Oncothyreon has enrolled the first patient in a Phase II trial to evaluate PX-866 in patients with glioblastoma multiforme that has recurred during or following primary therapy.

The single-arm screening trial is being conducted at seven centres across Canada, and will enrol up to 30 patients whose brain tumour is in first relapse during or following primary therapy.

The primary endpoint of the trial is a combination of objective response rate and early progression.

PX-866 is a small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase, a component of an important cell survival signalling pathway.